889 results on '"Raghavan, Derek"'
Search Results
2. Future cancer research priorities in the USA: a Lancet Oncology Commission
3. Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites
4. Testicular Cancer: The Test is to Focus on Important Research
5. Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network
6. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
7. Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients
8. Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging Problem
9. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer
10. Moving Molecular Oncology Into Community Practice: Follow the Yellow Brick Road
11. Outcomes of a Structured Education Intervention for Latinas Concerning Breast Cancer and Mammography
12. Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem
13. Invasive Bladder Cancer: Combined Modality Treatment
14. Principles of Chemotherapy for Genitourinary Cancer
15. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
16. Academic Hybrid Cancer Centers: Here Today, Gone Tomorrow?
17. Supplementary Table S2 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
18. Data from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
19. Co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET is low in metastatic urothelial carcinoma.
20. Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer
21. Abstract PR006: Screening under-served populations by mobile low dose computerized tomography (LDCT) scans results in stage shift with potential cures: Time for a change in health policy?
22. Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy
23. Multidisciplinary Care of Invasive Bladder Cancer: Emerging Roles of Chemotherapy
24. Principles of Chemotherapy for Genitourinary Cancer
25. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
26. Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
27. Urothelial Cancer
28. Renal Cell Carcinoma
29. Levine Cancer Institute Financial Toxicity Control Program: Expanding the program to reduce fiscal vulnerability of patients.
30. Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes
31. Prostate Cancer
32. A Structured Approach to Uncommon Cancers
33. Fundamentals of Cancer Treatment : Effects of Chemotherapy on Neoplastic Cells
34. Equity for under-served populations in lung cancer screening and treatment: Does mobile low-dose CT scanning lead to stage shift and diagnosis with potential cures at 4 years of follow-up?
35. Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle‑invasive bladder cancer
36. Predicting Low Trial Accrual Mathematically: Is That the Right Emphasis?
37. Considerations in the Use of Neoadjuvant and Adjunctive Systemic Chemotherapy in Treatment of Invasive Bladder Cancer by Cystectomy
38. Bladder Cancer
39. Interrelation of functional homologous recombination deficiency and hrr pathway alterations in prostate cancer.
40. Survival of young black males with metastatic clear cell renal cell carcinoma.
41. Total androgen blockade for prostate cancer: the end does not justify the means
42. Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients
43. Invasive Bladder Cancer: Combined Modality Treatment
44. Principles of Chemotherapy for Genitourinary Cancer
45. Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem
46. Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer
47. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma
48. Establishing prostate cancer patient derived xenografts: Lessons learned from older studies
49. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
50. A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.